DC Devices Inc. has raised US$9 Million from a consortium of investors. Lumira Capital joined the financing along with existing investors Third Rock Ventures and General Catalyst. Gerry Brunk, managing director of Lumira, joined the company’s board of directors. Tewksbury, Mass.-based DC Devices, a medical device company for the treatment of congestive heart failure, has been venture-backed since 2009.

trong>BAROnova has closed its Series C financing of $27.3 million, led by investments from Sante Ventures and Boston Scientific Corporation, an innovator of medical devices and technologies. Investors included Series B investors ONSET Ventures, Highland Capital Partners and Arboretum Ventures, along with new investor Lumira Capital. Financial terms were not disclosed.

Thrasos Therapeutics has raised $35 million for its treatment of acute kidney injury. SR One led the round, with additional funds coming from the GSK Canada Life Sciences Innovation Fund, SW Co., Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.

Ontario Venture Capital Fund (OVCF) has committed $70 million to three Ontario-focused VC funds: Lumira Capital II, Celtic House Venture Partners IV and Rho Canada Ventures II. PRESS RELEASE: Ontario Venture Capital Fund (OVCF) today announced it has recently made commitments totalling $70 million to three leading Ontario-focused venture capital funds: Lumira Capital II, Celtic House [...]

U-Systems, a developer of automated breast ultrasound technology, has closed on $6.5 million from investors including iD SoftCapital Group, Lumira Capital, PIIH, Radius Ventures, and Sycamore Ventures. The company will use the funds to complete a clinical study, and complete submissions for regulatory approval with the Food and Drug Administration. U-Systems is based in Sunnyvale, Calif.

Lumira Capital is planning to raise between $250 million and $300 million for its second fund, according to VentureWire. The Toronto-based VC firm was previously known as MDS Capital Corp., and focuses on the life sciences sector. www.lumiracapital.com